Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of controversy.

Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of controversy.

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review